Hormonal
Arachidonic acid exhibits schistosomicidal and tumoricidal activity by activating neutral sphingomyelinase (nSMase), leading to membrane disruption and cell death in parasites and cancer cells.
While ARA has potential schistosomicidal and tumoricidal properties in laboratory settings, it is not currently a standard standalone treatment for these conditions. Its primary role remains supporting normal physiological functions like membrane integrity and immune response. Do not self-treat cancer or parasitic infections with ARA supplements without medical supervision.
ARA was recently documented as activator of Schistosoma mansoni and S. haematobium tegument-associated neutral sphingomyelinase in a dose-dependent manner, eventually leading to their attrition in vitro and in vivo [74–77]. ... ARA was reported to kill tumor cells selectively in vitro via eliciting cell surface membrane lipid peroxidation...
Why this rating
Review of in vitro and animal studies; some human data for schistosomiasis combination therapy.
Source
Arachidonic acid: Physiological roles and potential health benefits – A review
Hatem Tallima et al. · Journal of Advanced Research · 2017
DOI 10.1016/j.jare.2017.11.004
More from this paper
- Dietary arachidonic acid (ARA) supplementation improves cognitive function in elderly individuals with low baseline serum ARA levels and enhances visual acuity and cognitive development in preterm infants when added to formula.Moderate
- Arachidonic acid supplementation affects body composition, muscle function, and power output in strength-training individuals.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →